Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antiparkinsonian

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Antiparkinsonian. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-002010-38 Sponsor Protocol Number: SC3-90049-001 Start Date*: 2005-11-21
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.)
    Full Title: Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson D...
    Medical condition: Advanced Parkinson´s Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006721-27 Sponsor Protocol Number: CERE-120-06 Start Date*: 2008-10-20
    Sponsor Name:Ceregene Inc.
    Full Title: A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2...
    Medical condition: idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-005234-39 Sponsor Protocol Number: 2939111 Start Date*: 2005-05-27
    Sponsor Name:Orion Corporation, ORION PHARMA, Finland
    Full Title: Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061536 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DK (Completed) FI (Completed) IE (Completed) DE (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2005-000434-21 Sponsor Protocol Number: LP1 Start Date*: 2005-06-15
    Sponsor Name:Kognitive Neurologie, Institut für Medizin, Forschungszentrum Jülich
    Full Title: Neurochemische Modulation von Exekutiv- und Gedächtnisfunktionen
    Medical condition: Progressive cognitive decline in physiological aging
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002643-27 Sponsor Protocol Number: 2939089 Start Date*: 2004-10-14
    Sponsor Name:Orion Pharma GmbH
    Full Title: Efficacy and tolerability of Comtess® versus Cabaseril® as add-on to levodopa in the treatment of Parkinsonian patients suffering from wearing- off phenomenon
    Medical condition: Parkinson´s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004865-26 Sponsor Protocol Number: M12-927 Start Date*: 2015-08-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkins...
    Medical condition: Non-motor symptoms in advanced Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Completed) IT (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001403-23 Sponsor Protocol Number: M15-535 Start Date*: 2017-02-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with ...
    Medical condition: Dyskinesia in advanced Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) GR (Completed) ES (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016360-37 Sponsor Protocol Number: PD 01/09 Start Date*: 2010-02-06
    Sponsor Name:Björn Holmberg
    Full Title: TREATMENT OF DYSKINESIAS IN PARKINSON’S DISEASE WITH OSU6162 – A PILOT STUDY
    Medical condition: Parkinsons disease is complicated by dyskinesias and dystonia. Due stabilizing properties, we believe (-)-OSU6162 may alleviate dyskinesias, without causing parkinsonism. Aim: To evaluate in a doub...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003254-17 Sponsor Protocol Number: IIBSP-SAF-2017-75 Start Date*: 2017-12-21
    Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau
    Full Title: A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Safinamide on Apathy in Patients With Parkinson's Disease
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-013885-14 Sponsor Protocol Number: P06-10/BF2.649 Start Date*: 2009-11-12
    Sponsor Name:BIOPROJET
    Full Title: A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week ope...
    Medical condition: Excessive daytime sleepiness in Parkinson?s Disease Somnolencia diurna excesiva en la enfermedad de Parkinson.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10015595 Excessive daytime sleepiness LLT
    12.0 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000980-10 Sponsor Protocol Number: CT-37527-13-0124 Start Date*: 2013-10-18
    Sponsor Name:Britannia Pharmaceuticals Limited
    Full Title: TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with mo...
    Medical condition: Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10034006 Parkinson's disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) ES (Completed) FR (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013886-24 Sponsor Protocol Number: P06-11 / BF2.649 Start Date*: 2010-03-03
    Sponsor Name:BIOPROJET
    Full Title: A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease
    Medical condition: Excessive daytime sleepiness in Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10015595 Excessive daytime sleepiness LLT
    12.0 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006043-32 Sponsor Protocol Number: F1J-IT-HMFQ Start Date*: 2007-02-21
    Sponsor Name:ELI LILLY
    Full Title: An open label pilot study on the tolerability of duloxetine in the treatment of depressed patients with Parkinson s disease
    Medical condition: outpatient
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012529-12 Sponsor Protocol Number: 0827703 Start Date*: 2009-06-10
    Sponsor Name:CHU de Toulouse
    Full Title: A randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease
    Medical condition: parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002496-14 Sponsor Protocol Number: 2939121 Start Date*: 2007-11-05
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, ...
    Medical condition: Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004507-23 Sponsor Protocol Number: 3112004 Start Date*: 2016-03-15
    Sponsor Name:Orion Corporation
    Full Title: Efficacy and safety of ODM-104 compared to a standard combination (Stalevo); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson's disease and end-of-dose wearin...
    Medical condition: Parkinson's disease (PD) patients with end-of-dose wearing-off (motor fluctuations)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) HU (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-023756-82 Sponsor Protocol Number: TUD-RaSPar-051 Start Date*: 2011-07-13
    Sponsor Name:Dresden University of Technology
    Full Title: Rasagiline treatment for Sleep disorders in Parkinson´s disease
    Medical condition: sleep disturbances/sleep disorders in patients with Parkinson´s disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016143-19 Sponsor Protocol Number: 09 196 07 Start Date*: 2010-02-23
    Sponsor Name:Michael J. Fox Foundation for Parkinson’s Research
    Full Title: VALIDATION OF DYSKINESIA RATING SCALES
    Medical condition: Maladie de parkinson
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-006004-16 Sponsor Protocol Number: 03PDE2020 Start Date*: 2021-07-16
    Sponsor Name:Celon Pharma S.A.
    Full Title: Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Diseas...
    Medical condition: Levodopa-induced dyskinesia in Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004112-21 Sponsor Protocol Number: VorDE-PD Start Date*: Information not available in EudraCT
    Sponsor Name:IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL
    Full Title: TOLERABILITY, SAFETY AND EFFICACY OF VORTIOXETINE FOR TREATMENT OF DEPRESSION IN PARKINSON’S DISEASE: A 16 WEEK OPEN LABEL STUDY
    Medical condition: Depression in Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10034007 Parkinson's disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:03:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA